

# Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

https://marketpublishers.com/r/C2FCC9F8C98EN.html

Date: January 2016

Pages: 28

Price: US\$ 225.00 (Single User License)

ID: C2FCC9F8C98EN

#### **Abstracts**

Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

The Competitive Intelligence Report Inhibitors of the bromodomain and extra-terminal domain (BET) family as of January 201 provides a competitor analysis in the development pipeline of novel small molecule pan, selective or dual target bromodomain and extra-terminal domain (BET) family inhibitors suitable for treatment of cancer, inflammatory and cardiovascular diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Bromodomains are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation. Bromodomains have attracted great interest as promising new epigenetic targets for diverse human diseases, including inflammation, cancer, and cardiovascular disease. The demonstration that two small molecule compounds, JQ1 and I-BET762, potently inhibit proteins of the bromodomain and extra-terminal (BET) family with potential for cancer and inflammatory disease sparked intense efforts in academia and pharmaceutical industry to develop novel bromodomain antagonists for therapeutic applications. Several BET inhibitors are already in clinical trials for hematological malignancies, solid tumors and cardiovascular disease.

The report includes a compilation of currently active projects in research and development of novel small molecules targeting for treatment of hematologic malignancies, solid tumors, inflammatory and cardiovascular diseases. In addition, the



report lists company-specific RD pipelines of BET Inhibitors. Competitor projects are listed in a tabular format providing Information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product category/Therapeutic Area,
Indication,
RD Stage and
additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of RD projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.



## **Contents**

Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family

**Table of Contents** 

Inhibitors of the bromodomain and extra-terminal domain (BET) family

Corporate BET Inhibitor R&D Pipelines



#### I would like to order

Product name: Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET)

family

Product link: <a href="https://marketpublishers.com/r/C2FCC9F8C98EN.html">https://marketpublishers.com/r/C2FCC9F8C98EN.html</a>

Price: US\$ 225.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

## **Payment**

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/C2FCC9F8C98EN.html">https://marketpublishers.com/r/C2FCC9F8C98EN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



